Reino Unido researchers presented results from a large study that advocates offering a simple finger prick test to detect type 1 diabetes early in children. The program, known as ELSA, has already analyzed thousands of young people and identified cases at an early stage, allowing interventions before serious complications occur. The initiative aims to reduce emergency diagnoses that lead to urgent hospitalizations.
The study involved more than 17,000 children between 3 and 13 years old, with blood samples collected using a non-invasive method. Especialistas highlight that early detection paves the way for treatments that control glucose levels and prevent diabetic ketoacidosis, a potentially fatal condition.
British health authorities are now evaluating the expansion of screening to all child age groups. The next phase of the project should include children from 2 years old.
How the screening test works
The test consists of a finger prick to collect a small amount of blood, which is analyzed for autoantibodies. Esses markers indicate that the immune system is attacking the cells in the pancreas responsible for producing insulin.
Children without autoantibodies have a very low risk of developing the disease. Já the presence of two or more markers signals the early stage of type 1 diabetes, even without visible symptoms.
The procedure can be performed at home, at school or in a doctor’s office. Famílias receive detailed guidance on how to safely collect the sample and send it for laboratory analysis.
Preliminary results from the ELSA study
The first phase of ELSA examined 17,283 children and identified 160 cases with multiple autoantibodies, indicating early-onset diabetes. Outros 75 had a single marker, which increases the future risk of the condition.
Seven children were diagnosed with previously undetected type 1 diabetes and started insulin treatment immediately. Esses numbers reinforce the effectiveness of the method in identifying the disease before serious clinical manifestations.
The study is funded by organizations specializing in diabetes and coordinated by British universities. Pesquisadores emphasize that population screening can transform disease management at a national level.
Benefits of early detection
Identifying type 1 diabetes in the early stages allows families to prepare for managing the condition. Pais and children receive education about glycemic monitoring and adjustments to their eating routine.
A intervenção precoce reduz significativamente o risco de cetoacidose diabética, que ocorre quando o organismo entra em crise por falta de insulina. Essa complication requires hospitalization and can cause permanent sequelae.
Children diagnosed early have better long-term metabolic control. Profissionais health monitors progress and adjusts therapies as needed.
Furthermore, screening offers peace of mind for families without positive markers. Elas know that the risk of developing the disease is minimal in the coming years.
Immunotherapy treatment
One of the study participants, a 12-year-old girl, started treatment with teplizumab, a medication that modulates the immune response. The therapy seeks to slow the destruction of insulin-producing cells in the pancreas.
Clinical trials have shown that the medication can delay the onset of symptoms by an average of three years. No Reino Unido, access is still limited, but selected cases already receive the infusion.
Teplizumab was recently approved for use in patients with early-stage disease. Especialistas consider the drug an important advance in the management of type 1 diabetes.
The combination of screening and immunotherapy represents a new preventive approach. Pesquisadores hope that more children will benefit from this strategy in the coming years.
Common symptoms of type 1 diabetes
Type 1 diabetes occurs when the pancreas stops producing enough insulin. The most common signs in children include increased thirst and urinary frequency.
- Excessive urination, especially at night;
- Intense thirst and increased fluid consumption;
- Constant fatigue and irritability;
- Weight loss for no apparent reason;
- Blurred vision in some cases.
Younger children may have heavier diapers or return to bed-wetting. Pais should observe these changes and seek medical evaluation quickly.
Experiences of participating families
Mothers and fathers report that prior knowledge of the condition brought emotional security. Eles can plan adjustments to school and eating routines before symptoms appear.
A mother with type 1 diabetes highlighted the difference in relation to the diagnosis itself, which occurred abruptly. The screening allowed gradual preparation for the daughter.
Professionals offer ongoing psychological and educational support. Families participate in monitoring groups to exchange experiences.
Voluntary participation in the study also contributes to scientific advances. Muitos parents see involvement as a way to help other children in the future.
Expansão do programa ELSA
Phase two of the study will expand screening to children ages 2 to 17 throughout the Reino Unido. The goal is to recruit tens of thousands of additional participants.
Researchers will prioritize younger age groups and teenagers. Essas groups present specific challenges in conventional diagnosis.
Testing remains simple and accessible, with collection options at different locations. Autoridades assess the feasibility of national implementation based on these data.
Other European countries have already adopted similar programs. Itália offers screening for children and adolescents from the first years of life.
Known risk factors
Genetic predisposition increases the chance of developing type 1 diabetes. First-degree Familiares with the condition have a high risk.
Environmental factors, such as viral infections, can trigger the autoimmune process in susceptible individuals. Estudos continue to investigate these interactions.
Children with a family history especially benefit from regular monitoring. Population screening, however, covers all profiles.
Experts reinforce that the disease is not related to lifestyle. Diferente of type 2, type 1 results from an immunological attack on the pancreas.
Perspectives for the future
The success of ELSA reinforces the possibility of routine screening in the British healthcare system. Decisões will depend on cost-benefit and logistics analyses.
Advances in immunotherapies complement the early detection strategy. Novos medications in development promise even greater delays in the disease’s progress.
International researchers follow the British results. Programas similar ones are gaining strength in other developed countries.
The initiative represents a paradigm shift in the management of type 1 diabetes. The focus shifts from reactive treatment to active prevention.